Plus Therapeutics (NASDAQ:PSTV) Shares Up 11.2% – Here’s Why

by · The Cerbat Gem

Plus Therapeutics, Inc. (NASDAQ:PSTV – Get Free Report)’s stock price shot up 11.2% during mid-day trading on Monday . The stock traded as high as $6.03 and last traded at $5.84. 276,334 shares were traded during trading, an increase of 42% from the average session volume of 194,504 shares. The stock had previously closed at $5.25.

Analyst Ratings Changes

PSTV has been the subject of several research analyst reports. D. Boral Capital reissued a “hold” rating on shares of Plus Therapeutics in a research report on Tuesday, March 31st. Wall Street Zen raised Plus Therapeutics to a “sell” rating in a research report on Saturday, April 4th. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective (down from $50.00) on shares of Plus Therapeutics in a research report on Friday, January 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Tuesday, April 21st. Finally, Ascendiant Capital Markets lowered their price objective on Plus Therapeutics from $475.00 to $65.00 and set a “buy” rating for the company in a research report on Thursday, April 9th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $58.00.

Read Our Latest Research Report on Plus Therapeutics

Plus Therapeutics Trading Up 10.3%

The firm has a market capitalization of $44.24 million, a P/E ratio of -2.80 and a beta of 1.40. The business has a 50-day moving average of $5.78 and a 200 day moving average of $9.26.

Plus Therapeutics (NASDAQ:PSTV – Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.20). Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%. The firm had revenue of $1.03 million during the quarter, compared to the consensus estimate of $0.97 million. As a group, research analysts forecast that Plus Therapeutics, Inc. will post -3.66 EPS for the current year.

Institutional Trading of Plus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PSTV. L1 Global Manager Pty Ltd bought a new stake in Plus Therapeutics in the 4th quarter valued at about $1,167,000. Jane Street Group LLC bought a new stake in Plus Therapeutics in the 4th quarter valued at about $525,000. Altium Capital Management LLC bought a new stake in Plus Therapeutics in the 3rd quarter valued at about $628,000. Geode Capital Management LLC increased its position in Plus Therapeutics by 72.5% in the 4th quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock valued at $719,000 after buying an additional 589,544 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Plus Therapeutics in the 4th quarter valued at about $254,000. 3.28% of the stock is owned by institutional investors.

Plus Therapeutics Company Profile

(Get Free Report)

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.

Recommended Stories